Nanexa: Positive first human NEX-20 PK results - ABG
PK data for NEX-20 confirms slow-release of lenalidomide Results in line with preclinical studies Nanexa will report Q2 tomorrow at 08:00 CET
ANNONS
NEX-20 human PK data shows lenalidomide slow release
Today Nanexa announced positive data from its Ph 1 NEX-20-01 study testing its slow-release lenalidomide formulation (NEX-20) in humans, confirming a controlled release of lenalidomide due to Nanexa's PharmaShell technology. The analysed samples came from nine healthy volunteers that received different doses of NEX-20 (ranging from 15 mg to 50 mg) via subcutaneous injection over a course of 21 days.
